Overnight ONSD Change as Non-Invasive Glymphatic Biomarker
Certainty: 0.50.
If glymphatic clearance operates primarily during sleep (Xie et al. 2013 (Xie et al. 2013) showed 60% interstitial space expansion during slow-wave sleep), then CSF volume should decrease overnight as waste is cleared. Optic nerve sheath diameter (ONSD), measured non-invasively via bedside ultrasound, correlates with intracranial pressure in IIH validation studies (r ≈ 0.7–0.8). This proposes that measuring ONSD at bedtime versus morning provides a surrogate for overnight glymphatic function: a decrease in ONSD from evening (10 PM) to morning (7 AM) would indicate effective overnight CSF clearance; no change or an increase would suggest glymphatic failure.
This approach addresses a critical gap identified in Phase 1: no non-invasive, repeatable measure of glymphatic function exists. It is immediately implementable with existing ultrasound equipment, costs nothing after the initial probe, and can be performed serially to track treatment response to Perrin Technique, CA inhibitors, or sleep interventions.
Technical rationale. CSF production occurs continuously at approximately 0.35 mL/min (21 mL/h). Overnight (9 hours at typical sleep duration), the choroid plexus produces ~189 mL. If glymphatic clearance during sleep is normal, this volume should be cleared, reducing intracranial pressure and CSF volume. ONSD reflects intracranial pressure dynamics continuously and responds rapidly to pressure changes (under 15 seconds for acute ICP elevation). Diurnal ONSD variation in healthy individuals is minimal (≤0.3 mm), but in IIH it shows larger fluctuations. In ME/CFS with glymphatic dysfunction, overnight clearance may be impaired, leading to either no decrease or paradoxical increase in ONSD (if CSF production continues without adequate drainage).
Applications.
- Screening tool: Identify ME/CFS patients with elevated ICP who might benefit from CSF volume reduction. ONSD >5.0 mm in supine position indicates possible intracranial hypertension requiring workup (lumbar puncture, MRI). Patients with normal supine ONSD but elevated morning ONSD may have overnight glymphatic failure.
- Treatment monitoring: Track ONSD changes during interventions. A successful Perrin Technique course or CA inhibitor therapy should produce a measurable decrease in morning ONSD (≥0.2 mm reduction from evening baseline). No change suggests inadequate drainage; increase suggests continued CSF production without improved clearance.
- Diagnostic stratification: ME/CFS patients can be stratified by ONSD pattern: “normalizer” (decrease with treatment) vs “non-responder” (no change or paradoxical increase). This could predict response to CSF drainage interventions.
- Dose titration guide: For CA inhibitors, titrate until morning ONSD stabilizes in target range (4.0–5.0 mm for ME/CFS—higher than IIH target of below 3.5 mm to account for pressure hypersensitivity described by Midtlien et al. 2024 (Midtlien et al. 2024)) while monitoring cognitive function.
Testable predictions.
- Healthy controls will show a consistent decrease in ONSD from evening to morning (≥0.2 mm), reflecting normal overnight glymphatic clearance
- ME/CFS patients will show either no decrease or a paradoxical increase in morning ONSD compared to evening, indicating glymphatic dysfunction
- ME/CFS patients who respond to CSF drainage interventions (Perrin, CA inhibitors, sleep optimization) will show normalization of ONSD diurnal pattern (decrease restored)
- Baseline morning ONSD (before treatment) will correlate with symptom severity: higher ONSD associated with worse brain fog, headache, and cognitive symptoms
- Adding CA inhibitors to non-responders (normal morning ONSD) will not reduce ONSD, confirming that impaired clearance, not excess production, is the primary deficit